Alzheimer s Disease Clinical Trials

67 recruitingLast updated: June 18, 2026

There are 67 actively recruiting alzheimer s disease clinical trials across 32 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4. Top locations include London, United Kingdom, Toronto, Ontario, Canada, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Alzheimer s Disease Trials at a Glance

67 actively recruiting trials for alzheimer s disease are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Not Applicable with 15 trials, with the heaviest enrollment activity in London, Toronto, and Beijing. Lead sponsors running alzheimer s disease studies include Bristol-Myers Squibb, Capital Medical University, and National Institute of Mental Health (NIMH).

Browse alzheimer s disease trials by phase

Treatments under study

About Alzheimer s Disease Clinical Trials

Looking for clinical trials for Alzheimer s Disease? There are currently 67 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Alzheimer s Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Alzheimer s Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 67 trials

Recruiting
Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

DementiaALSMild Cognitive Impairment+2 more
National Institute of Mental Health (NIMH)184 enrolled1 locationNCT04396873
Recruiting
Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

HealthyMild Cognitive ImpairmentAlzheimer s Disease
National Institute of Mental Health (NIMH)90 enrolled1 locationNCT07169630
Recruiting
Phase 1Phase 2

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Alzheimer s Disease
AbbVie210 enrolled10 locationsNCT07599670
Recruiting
Phase 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer s Disease
Alnylam Pharmaceuticals50 enrolled13 locationsNCT07214727
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Alzheimer s Disease
Bristol-Myers Squibb586 enrolled126 locationsNCT06976203
Recruiting

Crownlands Observing Progression With Neurons Study

Mild Cognitive Impairment (MCI)Alzheimer s Disease
Crownlands160 enrolled1 locationNCT07611396
Recruiting
Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

Alzheimer s Disease
Hoffmann-La Roche50 enrolled8 locationsNCT07234942
Recruiting
Phase 1Phase 2

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Alzheimer s DiseaseBeta-AmyloidProdromal Alzheimer's Disease+2 more
AC Immune SA304 enrolled26 locationsNCT05462106
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer s Disease
Bristol-Myers Squibb586 enrolled106 locationsNCT06976216
Recruiting

The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)

Alzheimer s Disease
University Hospital, Grenoble220 enrolled1 locationNCT07367880
Recruiting
Phase 1

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

Alzheimer DiseaseMild Cognitive ImpairmentAlzheimer s Disease
University of California, San Diego60 enrolled1 locationNCT06548191
Recruiting
Phase 2

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

Alzheimer s DiseaseMild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Weill Medical College of Cornell University20 enrolled1 locationNCT07553338
Recruiting
Phase 4

Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

Alzheimer Dementia (AD)Alzheimer s DiseaseMCI-AD, Early Stage Alzheimer's Disease
First Affiliated Hospital of Wenzhou Medical University200 enrolled1 locationNCT07604896
Recruiting
Phase 2

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Alzheimer s Disease
Novartis Pharmaceuticals407 enrolled65 locationsNCT07094516
Recruiting

Dominantly Inherited Alzheimer Network (DIAN)

Alzheimer s Disease
Washington University School of Medicine700 enrolled26 locationsNCT00869817
Recruiting
Not Applicable

Study on the Effect of 40 Hz Non-Invasive Light Therapy System

Alzheimer s Disease
Zealand University Hospital62 enrolled1 locationNCT05260177
Recruiting
Not Applicable

Social & Affective Cognition in Alzheimer's Disease & Associated Disorders

Alzheimer s DiseaseFrontotemporal Degeneration (Semantic & Behavioral Variants)
University Hospital, Lille120 enrolled1 locationNCT06338397
Recruiting
Not Applicable

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

DementiaBrain DiseasesCentral Nervous System Diseases+5 more
Advanced Technology & Communications180 enrolled11 locationsNCT06088121
Recruiting
Phase 1

Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study

Alzheimer s DiseaseFaecal Microbiota Transplantation (FMT)
University Hospital of North Norway10 enrolled1 locationNCT07332260
Recruiting

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

Alzheimer s Disease
Eisai Korea Inc.3,000 enrolled1 locationNCT06810960